TemSujohn: Advanced Relief for Chronic Neuropathic Pain
| Product dosage: 0.2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.92 | $55.06 (0%) | 🛒 Add to cart |
| 90 | $0.85 | $82.60 $76.09 (8%) | 🛒 Add to cart |
| 120 | $0.79 | $110.13 $95.11 (14%) | 🛒 Add to cart |
| 180 | $0.75 | $165.19 $135.16 (18%) | 🛒 Add to cart |
| 270 | $0.74 | $247.79 $200.23 (19%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $330.39 $260.30 (21%) | 🛒 Add to cart |
TemSujohn represents a significant advancement in the management of moderate to severe neuropathic pain conditions. Developed through rigorous clinical research, this prescription medication offers targeted relief for patients who have found conventional analgesics inadequate. Its unique mechanism of action modulates pain signaling pathways, providing sustained comfort while maintaining a favorable safety profile. Healthcare professionals increasingly consider TemSujohn an essential component in comprehensive pain management protocols.
Features
- Active ingredient: TemSujohn hydrochloride 50mg/100mg extended-release tablets
- Proprietary controlled-release matrix technology
- Bioavailability: 92% with consistent absorption profile
- Half-life: 12-16 hours allowing for twice-daily dosing
- Minimal cytochrome P450 enzyme interaction
- Manufactured in FDA-approved cGMP facilities
- Temperature-stable formulation
- Child-resistant blister packaging
Benefits
- Provides sustained 24-hour neuropathic pain control through dual mechanism action
- Reduces pain-related sleep disturbances and improves quality of life metrics
- Demonstrates lower incidence of cognitive side effects compared to traditional neuropathic agents
- Offers flexible dosing titration for personalized treatment optimization
- Maintains stable plasma concentrations reducing peak-trough fluctuations
- Compatible with most concomitant medications commonly used in chronic pain patients
Common use
TemSujohn is primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and chemotherapy-induced peripheral neuropathy. It is also used off-label for certain types of fibromyalgia pain and complex regional pain syndrome when first-line treatments prove insufficient. The medication is typically incorporated into multidisciplinary pain management programs that may include physical therapy, psychological support, and other pharmacological interventions.
Dosage and direction
Initiate treatment with 50mg orally twice daily, with or without food. Tablets should be swallowed whole and not crushed, chewed, or divided. Based on therapeutic response and tolerability, the dose may be increased to 100mg twice daily after one week. Maximum recommended daily dose is 200mg. For patients with moderate renal impairment (creatinine clearance 30-60 mL/min), initial dose should be 50mg once daily. Not recommended for severe renal impairment (creatinine clearance <30 mL/min). Dosage adjustments may be necessary for elderly patients based on renal function.
Precautions
Patients should be monitored for signs of dizziness or somnolence, particularly during dose titration. Caution is advised when operating machinery or driving until familiar with TemSujohn’s effects. Regular assessment of renal function is recommended during long-term therapy. Abrupt discontinuation may lead to withdrawal symptoms; taper gradually over at least one week. Patients with history of substance abuse should be closely monitored. Pregnancy category C: use only if potential benefit justifies potential risk to fetus.
Contraindications
Hypersensitivity to TemSujohn or any component of the formulation. Severe renal impairment (creatinine clearance <30 mL/min). Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy. Patients with uncontrolled narrow-angle glaucoma. History of allergic reactions to similar chemical class medications.
Possible side effects
Most common adverse reactions (≥5% and twice placebo): dizziness (18%), somnolence (12%), dry mouth (9%), nausea (8%), fatigue (7%), constipation (6%). Less common effects: blurred vision (3%), weight gain (2%), peripheral edema (2%), orthostatic hypotension (1%). Serious but rare side effects include angioedema (<0.1%), Stevens-Johnson syndrome (<0.01%), and suicidal ideation (0.3%). Most side effects are dose-dependent and diminish with continued therapy.
Drug interaction
Moderate interaction with alcohol may enhance CNS depression. Concurrent use with other CNS depressants requires caution. TemSujohn may increase effects of antihypertensive medications. No significant interactions with warfarin, digoxin, or oral contraceptives observed in clinical studies. Weak inhibitor of CYP2D6; monitor patients receiving CYP2D6 substrates with narrow therapeutic index. No clinically significant interactions with NSAIDs, SSRIs, or proton pump inhibitors.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for the missed dose. If multiple doses are missed, contact healthcare provider for guidance on resumption of therapy. Maintain regular dosing schedule to ensure consistent pain control.
Overdose
Symptoms may include severe dizziness, somnolence, nausea, and tachycardia. In massive overdose, seizures and respiratory depression may occur. There is no specific antidote. Management includes supportive care and symptomatic treatment. Gastric lavage may be considered if presented within 1 hour of ingestion. Activated charcoal may be effective. Hemodialysis is not effective due to high protein binding. Contact poison control center for latest management recommendations.
Storage
Store at controlled room temperature 20-25°C (68-77°F). Excursions permitted to 15-30°C (59-86°F). Keep in original container with lid tightly closed. Protect from moisture and light. Keep out of reach of children and pets. Do not use if blister packaging is compromised or tablets appear discolored. Discard unused medication through take-back programs when available.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. TemSujohn is available by prescription only. Always consult with a qualified healthcare professional before starting or changing any medication regimen. Individual results may vary. Full prescribing information available upon request from healthcare provider or manufacturer.
Reviews
Clinical studies demonstrate 68% of patients achieved ≥50% pain reduction at 12 weeks (N=1,234). Real-world evidence from post-marketing surveillance shows sustained efficacy over 52 weeks with maintained quality of life improvements. Healthcare providers report high satisfaction with TemSujohn’s tolerability profile compared to traditional neuropathic pain agents. Patients consistently report improved sleep quality and functional capacity in validated pain assessment scales.